Veracyte, Inc.
VCYT
$58.71
$1.953.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 541.74M | 517.15M | 495.14M | 479.13M | 463.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 541.74M | 517.15M | 495.14M | 479.13M | 463.39M |
| Cost of Revenue | 153.09M | 150.27M | 151.86M | 147.33M | 143.21M |
| Gross Profit | 388.65M | 366.88M | 343.28M | 331.80M | 320.19M |
| SG&A Expenses | 210.54M | 217.97M | 212.41M | 209.40M | 205.93M |
| Depreciation & Amortization | 13.23M | 13.15M | 13.43M | 13.90M | 14.40M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 457.06M | 452.20M | 446.96M | 441.48M | 434.59M |
| Operating Income | 84.68M | 64.94M | 48.18M | 37.65M | 28.80M |
| Income Before Tax | 90.75M | 68.20M | 31.01M | 28.97M | 35.08M |
| Income Tax Expenses | 2.73M | 1.85M | 693.00K | 2.63M | 2.03M |
| Earnings from Continuing Operations | 88.01 | 66.35 | 30.32 | 26.34 | 33.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.01M | 66.35M | 30.32M | 26.34M | 33.05M |
| EBIT | 84.68M | 64.94M | 48.18M | 37.65M | 28.80M |
| EBITDA | 106.17M | 86.36M | 70.55M | 60.63M | 52.03M |
| EPS Basic | 1.11 | 0.84 | 0.39 | 0.34 | 0.43 |
| Normalized Basic EPS | 0.83 | 0.65 | 0.49 | 0.42 | 0.33 |
| EPS Diluted | 1.08 | 0.82 | 0.38 | 0.33 | 0.41 |
| Normalized Diluted EPS | 0.81 | 0.64 | 0.48 | 0.42 | 0.32 |
| Average Basic Shares Outstanding | 315.83M | 314.32M | 312.75M | 311.04M | 309.19M |
| Average Diluted Shares Outstanding | 320.78M | 319.53M | 318.04M | 316.82M | 315.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |